Atlas Biotech

Atlas Biotech is a biotechnology company that provides functional genomics and deep mutational scanning (DMS) services to support drug discovery and precision medicine. The company’s flagship platform, Atlas qDMS, enables researchers to generate quantitative, dose-aware data by measuring IC50 values for thousands of protein variants in parallel. By utilizing synthetic saturation mutagenesis, patient-derived cell models, and high-throughput sequencing, the platform identifies functional hotspots and drug resistance mechanisms while accounting for translational pharmacology to bridge the gap between in vitro experimental data and clinical reality. In addition to its core scanning capabilities, the company offers specificity screening services to evaluate drug selectivity and reduce off-target effects, as well as broader functional genomics research to assist in target validation and biomarker identification.

These capabilities are designed to help pharmaceutical and biotechnology partners de-risk their drug development pipelines, optimize lead compounds, and inform clinical trial design. By identifying potential liabilities, such as resistance mutations or toxicity issues, before drugs reach the clinic, the company aims to improve success rates in oncology and other therapeutic areas. Atlas Biotech’s workflow assists clients in refining patient stratification strategies, understanding the mechanisms behind failed trials, and repurposing existing therapies. The company was founded in 2024 by a team with expertise in evolution, drug resistance, and structural oncology, operating from State College, Pennsylvania.